Lv2
110 积分 2024-09-12 加入
One thousand health-related quality-of-life estimates
17小时前
待确认
Cost-effectiveness analysis of pembrolizumab plus chemotherapy for patients with recurrent or metastatic cervical cancer in China
8天前
已完结
Cost Effectiveness of Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma in the USA
6个月前
已完结
Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
6个月前
已完结
Cost Effectiveness of Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma in the USA
6个月前
已完结
HTA28 A Comparative Review of Pharmacoeconomic (PE) Guidelines in ASIA-Pacific (APAC) with Europe and North America
8个月前
已完结
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
9个月前
已完结
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study[J]. Lancet Respir Med
9个月前
已完结
皖公网安备34019202002308
